Discrepancies between primary tumor and metastasis: impact on personalized medicine

被引：8
|
作者：
Vignot, Stephane [1 ,2 ]
Soria, Jean-Charles [1 ,3 ]
机构：
[1] Inst Gustave Roussy, Inserm U981, F-94805 Villejuif, France
[2] Grp Hosp Pitie Salpetriere Charles Foix, F-75013 Paris, France
[3] Inst Gustave Roussy, Serv Innovat Therapeut & Essais Proc, F-94805 Villejuif, France
来源：
BULLETIN DU CANCER | 2013年 / 100卷 / 06期
关键词：
personalized medicine; discrepancies; primary tumor; metastasis; BREAST-CANCER; CORE-NEEDLE; BIOPSIES; HETEROGENEITY; IMMUNOHISTOCHEMISTRY; RECOMMENDATIONS; EXPRESSION; BIOLOGY; CHEST; HER2;
D O I：
10.1684/bdc.2013.1767
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Molecular characterization of tumors is critical for the development and appropriate use of many anti-cancer agents. Potential discrepancies between primary tumor and secondary lesions lead to question on the optimal modalities for evaluation of biomarkers. In light of recent data, the need of iterative biopsies in metastatic setting has been suggested but technical and methodological limits in such analyses should not be ignored and this strategy can not be definitively validated. The evaluation of spatial and temporal variability of biomarkers in solid tumors should take into account tumoral context and therapeutic history of each patient for the development of personalized medicine in oncology.
引用
收藏
页码：561 / 568
页数：8
相关论文
共 50 条
  • [41] An organoids biobank for recapitulating tumor heterogeneity and personalized medicine
    Hui Yang
    Ning Zhang
    Yu-Cun Liu
    ChineseJournalofCancerResearch, 2020, 32 (03) : 408 - 413
  • [42] Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine
    Seguin, Laetitia
    Durandy, Manon
    Feral, Chloe C.
    CANCERS, 2022, 14 (07)
  • [43] Next Generation Tumor Explant Technologies For Personalized Medicine
    Adine, C.
    Fernando, K.
    Ho, N.
    Iyer, N.
    Fong, E.
    TISSUE ENGINEERING PART A, 2023, 29 (9-10)
  • [44] Circulating Tumor Cells: Personalized Medicine in Interventional Oncology?
    Sheth, Rahul A.
    Hesketh, Robin
    Deipolyi, Amy R.
    Oklu, Rahmi
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2013, 24 (02) : 221 - 228
  • [45] An organoids biobank for recapitulating tumor heterogeneity and personalized medicine
    Yang, Hui
    Zhang, Ning
    Liu, Yu-Cun
    CHINESE JOURNAL OF CANCER RESEARCH, 2020, 32 (03) : 408 - 413
  • [46] Circulating Tumor DNA: The Future of Personalized Medicine in Oncology?
    Ryder, Christopher B.
    Schmotzer, Christine L.
    CLINICAL CHEMISTRY, 2015, 61 (02) : 443 - 444
  • [47] DIFFERENCE AND AGREEMENT BETWEEN THE PRIMARY LESION AND METASTASIS OF CANCER, WITH REFERENCE TO THE STROMA OF THE TUMOR
    SATO, H
    SUZUKI, M
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1981, 11 : 159 - 165
  • [48] Receptor discordance between primary tumor and metastasis influences CTC-status
    Stefanovic, S.
    Deutsch, T. M.
    Riethdorf, S.
    Fischer, C.
    Hartkopf, A.
    Sinn, P.
    Feisst, M.
    Pantel, K.
    Hennigs, A.
    Golatta, M.
    Suetterlin, M.
    Schneeweiss, A.
    Wallwiener, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (10) : E206 - E207
  • [49] Rare primary tumor but frequent metastasis
    Mauger, D.
    Favriel, J. -M.
    Henno, S.
    Heresbach, D.
    ACTA ENDOSCOPICA, 2009, 39 (06) : 466 - 467
  • [50] Mobile Health Technology for Personalized Primary Care Medicine
    Shaw, Ryan J.
    Bonnet, Jonathan P.
    Modarai, Farhad
    George, Aaron
    Shahsahebi, Mohammad
    AMERICAN JOURNAL OF MEDICINE, 2015, 128 (06): : 555 - 557
12345